The recent US-UK drug deal is projected to cause 229,000 excess deaths in England by 2036, according to analysis published in the British Medical Journal. The deal, hailed by ministers as a way to avoid US tariffs on British medicine exports, could divert approximately £45 billion from essential NHS services, severely impacting public health.
Impact of the US-UK Drug Deal on NHS Funding
Under the terms of the trade agreement reached last December, the NHS is expected to pay 25% more for new medicines over the next decade. This increase will result in an annual cost surge to the NHS, potentially reaching £8.8 billion by 2036. Critics argue that this funding diversion will lead to significant cuts in other critical health services.
According to the analysis, without additional funding, the NHS will have to reallocate funds to cover the higher costs of medications, resulting in reduced spending on vital health services. The expected consequences are dire, with a projected increase in avoidable deaths surpassing the number of fatalities during the Covid-19 pandemic.
Political Reactions and Concerns
Ministers have defended the trade deal, asserting it is essential for maintaining access to innovative therapies for patients. However, health experts and opposition MPs have expressed skepticism about the deal's implications. Helen Morgan, the Liberal Democrat health spokesperson, described the situation as alarming, stating, "It is a complete insult to patients who are suffering and dying on hospital trolleys."
